Management of bleeding complications in redo cardiac operations

Annals of Thoracic Surgery

Volumn 65, Issue 4 SUPPL., 1998, Pages S2-

  Smith, Craig R ^a,b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Milstein Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; APROTININ; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR 9A INHIBITOR; BLOOD SUBSTITUTE; DESMOPRESSIN; ERYTHROPOIETIN; HEMOSTATIC AGENT; ILOPROST; NAFAMSTAT MESILATE; PROTHROMBIN; THROMBIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ASSISTED CIRCULATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; HEART SURGERY; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REOPERATION; REVIEW; THROMBOSIS;

EID: 0031960143     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00070-8     Document Type: Article

References (29)

1. Ray MJ, Marsh NA, Hawson GA. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. Blood Coag Fibrinol. 5:1984;679-685.
2. Jung G, Razafindranaibe F, Elkouby A, Durashel P, Penes F, Monassier JP. Modification in platelet shape and change in ATP release during CPB. Haemostasis. 25:1995;149-157.
3. Wahba A, Rothe G, Schmitz G, Birnbaum DE. Heparin effect on platelets and fibrinolysis. Ann Thorac Surg. 61:1996;1590-1591.
4. Bertolino G, Locatelli A, Noris P, et al. Platelet composition and function in patients undergoing CPB for heart surgery. Haemotologica. 81:1996;116-120.
5. Boldt J, Knothe C, Welters I, Dapper FL, Hemplemann G. Normothermic versus hypothermic cardiopulmonary bypass do changes in coagulation differ? Ann Thorac Surg. 62:1996;130-135.
6. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 73:1990;1119-1126.
7. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 101:1991;958-967.
8. Lu H, Soria C, Commin PL, et al. Hemostasis in patients undergoing extracorporeal circulation the effect of aprotinin (Trasylol) . Thromb Haemost. 66:1991;633-637.
9. Royston D. Preventing the inflammatory response to open-heart surgery the role of aprotinin and other protease inhibitors . Int J Cardiol. 53:1996;S11-S37.
10. Musial J, Niewiarowski S, Hershock D, et al. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med. 105:1985;514-522.
11. Adelman B, Michelson AD, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood. 68:1986;1280-1284.
12. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;788-796.
13. Royston D. High-dose aprotinin therapy a review of the first five years' experience . J Cardiothorac Vasc Anesth. 6:1992;76-100.
14. Davis R, Whittington R. Aprotinin a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery . Drugs. 49:1995;954-983.
15. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 107:1994;543-551.
16. Levy JH, Pifarré R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244.
17. Freeman JG, Turner GA, Venavbles LW, Latner AL. Serial use of aprotinin and incidence of allergic reactions. Curr Med Res Opin. 8:1983;559-561.
18. LaFerla GA, Murray WR. Anaphylactic reaction to aprotinin despite negative ocular sensitivity. Br Med J (Clin Res Ed). 289:1984;1176-1177.
19. Rose EA, Levin HR, Oz MC, et al. Artificial circulatory support with textured interior surfaces a counterintuitive approach to minimizing thromboembolism . Circulation. 90:(Suppl 2):1994;87-91.
20. Graham TR, Dasse K, Coumbe A, et al. Neo-intimal development on textured biomaterial surfaces during clinical use of an implantable left ventricular assist device. Eur J Cardiothorac Surg. 4:1990;182-190.
21. Slater JP, Rose EA, Levin HL, et al. Low thromboembolic risk without anticoagulation using advanced design left ventricular assist devices. Ann Thorac Surg. 62:1996;132-137.
22. Spanier T, Oz M, Levin H, et al. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg. 112:1996;1090-1097.
23. Goldstein DJ, Seldomridge JA, Chen JM, et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg. 59:1995;1063-1067.
24. Sun BC, Spanier TB, Choudhri AF, Oz MC. Factor IX concentrates initiate hemostasis in LVAD patients with intractable postoperative hemorrhage. J Heart Lung Transplant. 16:1997;95.
25. Osterurd B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII additional pathway for initiating blood coagulation . Proc Natl Acad Sci. 74:1977;5260-5264.
26. Lollar P, Fass DN. Inhibition of activation porcine factor IX by dansyl-glutamyl-glycl-arginyl-chloromethylketone. Arch Biochem Biophys. 233:1984;438-446.
27. Braunstein KM, Noyes CM, Griffith MJ, Lundblad RL, Roberts HR. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. J Clin Invest. 68:1981;1420-1426.
28. Benedict CR, Ryan J, Wolitzky B, et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 88:1991;1760-1765.
29. Spanier TB, Oz MC, Minanov O, Stern D, Rose E, Schmidt AM. Active site blocked factor IXa (IXai): a novel selective anticoagulant for use in CPB. Presented at the 83rd Clinical Congress of the American College of Surgeons, Chicago, IL, Oct 12-17, 1997.